TACR1 and cancer: NK1R blockage resulted in dose-dependent growth reduction in CSC-like cells, parental PDAC cells, and to a lesser degree in primary PSCs, whereby the highest sensitivity was observed in aggressive cancer cell types and subgroups expressing higher levels of the truncated TACR1 variant.